Effective clearance of inorganic phosphate (Pi) is more variable between dialysis treatments done in the same patient than that of the classic albeit non-toxic solute urea. This is the result of a detailed study by Debowska et al. [1] published in this issue of NDT where the amount of solute removed and the corresponding concentration profile were measured during intra-and inter-dialytic phases of three dialysis treatments delivered within the standard weekly schedule. The authors bypassed mechanistic aspects of kinetic modelling and measured the concentration profiles and the amounts of Pi, urea and creatinine removed for the midweek dialysis cycle as well as for the whole weekly cycle and quantified the treatment by equivalent continuous clearance (ECC) for these solutes. This measure, which allows for the comparison of treatment schedules with regard to treatment timing, is easily understood when compared with the familiar issue of multiple drug dosing. As with drugs administered at a fixed dose and at constant intervals, the concentration profile and the average concentration at steady state can be expected to deviate from that after the first administration (or a single administration) because of drug accumulation. Quite analogously, the concentration profile of solutes removed by dialysis depends on treatment frequency and treatment interval because solute is incompletely removed by a single dialysis treatment.
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ECC is the (hypothetical) clearance continuously delivered to provide a steady-state concentration that is equal to a reference concentration of the intermittent treatment. The concept was first introduced to compare intermittent dialysis with continuous renal function [2] and then to compare different treatment schedules such as standard, daily and nocturnal dialyses.
It is assumed that the system is in a steady state. The standard dialysis schedule with three treatments per week, comprising one long and two short intervals, is asymmetric (not evenly spaced), and, everything else being equal, the steady state is therefore defined for the whole cycle spanning 1 week. Single treatments such as the midweek treatment do not represent the steady state. The asymmetry of the standard treatment schedule appears to be small, but the effects are evident also from the results of this study, where midweek ECC was 10-30% larger than weekly ECC for all solutes studied [1] . This is expected, as solute profiles will be lower for midweek treatments. Therefore, to examine the features and benefits of ECC regarding variability of delivered dose, the comparison is better done for complete cycles and/or for individual but identical weekday treatments of subsequent cycles. This, however, requires longer observation phases. To avoid doubling of work and time, the comparison could also be done using the symmetric every other day schedule [3] , where, after some run-in time, single and multiple treatments are in steady state by definition.
It is further assumed that solute generation and endogenous clearance are the same with continuous or intermittent therapy [4] . However, it has been shown that protein catabolic rate and urea nitrogen appearance is higher after short dialysis intervals [5] . Thus, the increase in ECC for urea during midweek treatments can be explained by higher urea generation rates. Similarly, food, fluid intake and overall ultrafiltration have been shown to increase when switching from standard to daily dialysis [6] . One can speculate that this may affect intestinal Pi absorption. The intestinal microbiome binds Pi [7] and is affected by uraemia [8] . A diet high in soluble fibre is probably helpful to bind more Pi and to remove more Pi because of shortened intestinal transit time [9] . Furthermore, the effects of convective solute removal by ultrafiltration during dialysis and solute dilution by fluid volume accumulation between treatments also need to be considered.
ECC is calculated for a reference concentration such as time average, peak, peak average and treatment time average concentration as in the study by Debowska et al. [1] or other concentrations such as treatment average deviation [10] . However, there is no agreement for the proper reference concentration. The choice for a reference concentration can be justified by solute toxicity, which might be better described by peak (as with many drugs) or by time-averaged concentrations (as with glucose), or by practical aspects because a few pre-dialysis peak concentrations are more easily measured than whole weekly concentration profile. Some concentrations are more susceptible to aspects of I N FO C U S treatment timing than others [11, 12] . Other concentrations, such as time average concentration are more susceptible to compartment effects because they include the post-dialysis rebound phase. This may be essential for sequestered solutes such as Pi. Indeed, ECC based on treatment time overestimated ECC based on the whole treatment phase for all solutes by 21-37%, and the largest difference was found for Pi [1] . Taken together, the choice of reference concentrations is quite arbitrary. This adds to the uncertainty of defining one ECC, and it is likely to prevent general acceptance in clinical practice.
Urea (60 g/mol), creatinine (113 g/mol) and Pi (96 g/mol) have comparable molecular masses and therefore also comparable diffusion coefficients [13] . Extracorporeal clearance of Pi and creatinine, however, is much smaller because these solutes are essentially only cleared from plasma water flow, whereas urea is also cleared from red blood cells passing the dialyser [14] . Moreover, the negatively charged protein layer covering the dialyser fibres reflects Pi. For solutes with comparable dialyser clearance, differences in ECC are related to compartment effects.
The major difference between Pi, urea and creatinine is that phosphate is a core component of many organic molecules (DNA, RNA and ATP), metabolic pathways (glucose-6-phosphate), intracellular signals (c-AMP, IP6), membranes (phospholipids), cells and tissues (bone). Pi is involved in acidbase balance where bone serves as a reservoir for base (Ca 2+ ) especially with metabolic acidosis and where Pi serves as buffer for renal acid excretion. The same hormones that release Ca 2+ from this pool stimulate the release of Pi from intracellular stores. It is therefore evident that the concentration of Pi in extracellular fluid is embedded in the control of Ca 2+ and acidbase balance, and pre-dialysis Pi levels therefore can be expected to increase with the degree of metabolic acidosis [15] . Even though the kidneys play a key role in the control of Pi, Ca 2+ and acid-base balance, absence of renal control in end-stage kidney disease patients does not eliminate all control mechanisms and Pi does not become a passive solute such as urea or creatinine [16] .
Pi has been resistant to classic kinetic modelling in dialysis. Pi concentrations level off during dialysis or even increase late during dialysis in spite of constant extracorporeal clearance [17] . As a consequence, Pi removal does not decrease and importantly benefits from extending the treatment time [18, 19] . On the other hand, with excessively prolonged clearance such as during nocturnal dialysis, Pi has to be added to the dialysate to prevent extracellular Pi depletion [20] . So, the intracellular Pi stores are not infinite. More complex models incorporating active control mechanisms have been proposed, but the validity of model parameters and control gains and the applicability to a wide range of treatment conditions remains to be confirmed [21, 22] . On the other hand, very simple models appear to perform well for standard conditions [23] . In these passive models, it is inherently assumed that the half-life of control actions is much longer compared with the perturbation caused by a few hours of dialysis.
Based on identical urea reductions (Cpost/Cpre), the same Kt/Vurea was delivered for each of the weekly treatments. Again, if the single dose of a multiple dosing regimen is analysed in the steady state, the single dose will provide a useful measure of treatment dose [24] [2] . To be used for individual prescription, these values need to be scaled to body size such as distribution volume or body surface area, thereby further inflating the number of possible prescriptions for one solute. Expanded to other solutes, the numbers increase even further. Unless the number of possibilities cannot be reduced, this approach is of interest to research but not suitable for clinical practice.
Kt/Vurea is criticized for its 'one number fits all' approach, but the benefits can also be seen in the study by Debowska et al. [1] , especially when dealing with the standard treatment schedule [25] . The benefits of ECC are with comparison of different treatment schedules, such as starting dialysis twice a week in the presence of sufficient residual renal function [26, 27] , with symmetric every other day dialysis [28] , or with daily dialysis, but this was not studied here.
It is our understanding that, for a given Kt/Vurea and for a given treatment time t, the clearance and removal of other solutes will be in proportion to the clearance and the removal of urea. The proportions may be more stable such as with creatinine, or more variable, such as with Pi. Importantly, when the same Kt/Vurea is delivered during longer treatments or with increased convection such as high-flux dialysis or online haemodiafiltration, the proportions of other solutes removed are expected to increase [29] . The exact proportions, however, are unknown for most solutes, and not only depend on the steady state achieved in dialysis but on variation in nutritional uptake and metabolism. The study of Debowska et al. [1] documents the variability and relationship of solute removal for urea, creatinine and Pi in stable dialysis [1] . Unfortunately, it is not clear whether this variability should be routinely measured and whether treatment prescription should be changed.
Variability of solute removal between dialysis treatments is a well-known problem [30] . When small solute removal is assessed once per month, the dialysis dose measured on that occasion may not be representative of the whole month. This was one of the reasons to measure solute removal with every treatment using online clearance monitors [31] [32] [33] . As these monitors make use of standard machine components, the measurement comes at no additional cost, an important factor in haemodialysis. However, the variability remains [34] . Variability can be ascribed to extracorporeal factors such as effective blood flows determined by pump setting and arterial line pressures [35] , dialyser fibre clotting, dialysate bypass in case of machine alarms or with silent routine online tests of highflux dialysers, and to patient factors such as access function, variation in haematocrit and haemodynamic stability [36] . And with regard to phosphate, a higher variability is not unexpected for reasons mentioned earlier [37] .
Whether the approach to measure solute clearance with every treatment can be extended to phosphate remains to be determined. Also, the calculation of ECC requiring multiple blood sampling is not feasible in everyday dialysis. A convenient technique would have to be reagent-free and most likely based on optical means [38, 39] . Such techniques are available for dialysis, but certainly, they are going to make dialysis machines more expensive [40] .
In summary, the study reminds us that dialysis treatments are more variable even when perfectly controlled in an experimental set-up and that extrapolation of solute removal from one solute to another includes major uncertainties. This is especially important for phosphate quantification.
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